Lorundrostat shows promise for uncontrolled, treatment-resistant hypertension
Lorundrostat, a selective aldosterone synthase inhibitor, shows blood pressure -lowering potential in people with uncontrolled and treatment-resistant hypertension, according to the Advance-HTN trial.
